Iriyama, Chisako
Murate, Kenichiro
Iba, Sachiko
Okamoto, Akinao
Yamamoto, Hideyuki
Kanbara, Ayana
Sato, Akane
Iwata, Emiko
Yamada, Ryuta
Okamoto, Masataka
Watanabe, Hirohisa
Mutoh, Tatsuro
Tomita, Akihiro http://orcid.org/0000-0002-5391-1399
Funding for this research was provided by:
Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (15K09473, 21K08407)
Article History
Received: 13 September 2021
Accepted: 26 September 2021
First Online: 2 October 2021
Change Date: 27 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00277-021-04722-6
Declarations
:
: The study protocol was approved by the institutional review boards at Fujita Health University (approval number, HG17-032, HG18-017 and HG20-055).
: A.T.: research funding: Chugai Pharmaceutical, Astellas Pharma, Eisai, Otsuka Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin, Shionogi, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Teijin, Nippon Shinyaku, Nihon Pharmaceutical, Pfizer Japan, Mochida Pharmaceutical, Yakult Honsha, and Perseus Proteomics. Lecture fee: Chugai Pharmaceutical, Kyowa Kirin, Eisai, Takeda Pharmaceutical, Astellas Pharma, Nippon Shinyaku, Janssen Pharmaceutical, Zenyaku Kogyo, AbbVie GK, Bristol-Myers Squibb, and SymBio Pharmaceutical.